China Dismisses Two Researchers After Six-Year-Old Girl Dies in Experimental Gene-Editing Treatment
SHANGHAI: Chinese authorities have dismissed two researchers and imposed disciplinary measures on several medical officials following an investigation into the death of a six-year-old girl who died after receiving an experimental gene-editing treatment at a hospital in Shanghai.

The case has raised serious questions about medical research ethics, patient safety and the supervision of advanced genetic treatments, particularly when experimental procedures involve children with rare diseases.
The girl, identified by the pseudonym Mei in earlier media investigations, suffered from Snijders Blok-Campeau syndrome, a rare genetic condition affecting neurological development. Her family approached researchers in the hope that an experimental treatment could correct the genetic mutation responsible for her condition.
The treatment was administered at Shanghai Xinhua Hospital in March 2025. However, the child’s health deteriorated following the procedure, and she died seven days after receiving the experimental therapy.
Experimental Treatment Ends in Tragedy
The research team had been developing a personalised base-editing treatment designed to correct a specific genetic mutation associated with the girl’s condition.
Base editing is an advanced form of gene-editing technology that allows scientists to change individual DNA letters without cutting both strands of the DNA molecule.
Researchers had conducted laboratory and animal experiments before moving towards human treatment.
The experimental therapy used modified viruses to deliver genetic editing instructions into the patient’s central nervous system.
However, the procedure carried significant risks, including potentially severe immune reactions.
Following the child’s death, the hospital’s ethics committee concluded that the fatal complication was related to the gene therapy. The identified cause was thrombotic microangiopathy, a serious condition involving damage to small blood vessels and blood clots.
Investigation Uncovers Serious Research Failures
An investigation organised by Shanghai authorities examined the research process, clinical procedures, scientific publications and the responsibilities of the institutions involved.
Investigators identified several shortcomings in the way the experimental treatment was developed and administered.
One major concern involved the handling of safety information from earlier animal experiments. The research team failed to communicate important warning signs from non-human primate studies to the doctors responsible for the clinical treatment.
As a result, potentially significant safety concerns were not adequately considered before the child received the experimental therapy.
Investigators also found that the hospital’s scientific review and ethics approval procedures were insufficient.
Although additional safety documentation had been requested, the ethics committee approved the treatment without receiving all the necessary supporting information.
The informed consent process was also found to have deficiencies, particularly regarding the disclosure of the possibility of death.
Two Researchers Dismissed
Following the investigation, authorities imposed disciplinary measures against several individuals.
The two principal researchers, identified in the official investigation as Qiu and Yang, were dismissed from their positions.
They were also barred for five years from participating in government-funded scientific projects, research awards and related professional activities.
Their names were entered into China’s serious scientific research misconduct database.
Other officials involved in overseeing the clinical research and hospital ethics procedures also received disciplinary penalties, including removal from administrative positions, reductions in professional grades and restrictions on future responsibilities.
The institutions involved were instructed to review their internal management systems and strengthen research supervision.
Financial Arrangements Raise Ethical Questions
The investigation also examined financial arrangements connected with the experimental treatment.
According to the official findings, the girl’s family contributed approximately 5.337 million yuan to support different parts of the research project.
The payments included funding for the production of viral vectors, animal safety studies and a donation to an educational development foundation.
Investigators also found that the family had provided money and valuable gifts to certain members of the research team.
The total value of these benefits was approximately 1.06 million yuan.
Authorities reported that the relevant money and property had been returned or handed over in accordance with the investigation’s requirements.
These findings have raised questions about financial transparency, conflicts of interest and the responsibilities of researchers when families are desperate to obtain treatments for children with rare conditions.
Scientific Publication Also Comes Under Scrutiny
The investigation examined a research paper published in the scientific journal Nature in February 2026.
The publication described experimental work involving the development of the gene-editing approach.
Authorities reported that they did not find evidence of fabricated research data.
However, they identified academic irregularities, including differences between the actual research methods and the descriptions presented in the publication, as well as the presentation of data collected during the same experimental period without adequate explanation.
Investigators also found that important safety findings and the negative clinical outcome had not been appropriately disclosed when the research was published.
These findings have intensified discussions about scientific transparency and the importance of reporting unsuccessful or harmful clinical outcomes.
China Moves to Strengthen Medical Research Oversight
The case has prompted renewed attention to the regulation of advanced biomedical research in China.
Gene-editing treatments have considerable potential to address inherited diseases, certain cancers and other conditions that currently have limited treatment options.
However, these technologies can also create serious risks, particularly when used in experimental procedures involving children or when researchers have limited experience with a particular treatment.
Shanghai authorities have announced additional inspections of clinical research involving emerging biomedical technologies.
The government has also called for stronger institutional supervision, better ethical reviews and more comprehensive safety assessments before experimental treatments are administered to patients.
A Wider Warning for the Future of Gene Editing
The death of the young patient highlights the difficult balance between scientific innovation and medical responsibility.
For families dealing with rare and potentially life-changing conditions, experimental treatments can offer hope when conventional medicine provides few options.
However, that hope must be supported by transparent information, independent safety assessments and clear explanations of potential risks.
The case demonstrates why advanced medical research requires strict ethical standards, particularly when vulnerable patients are involved.
As gene-editing technology continues to develop, the protection of patients must remain central to scientific progress.
The investigation’s findings are likely to contribute to wider international discussions about clinical trial supervision, research integrity and the responsibilities of scientists developing personalised genetic treatments.